PubMed Health⌕ Search

Biomedical subjects

C L Hanna

Publications and source records attributed to C L Hanna.

5 recordsLinked to original sources
PubMed2002

Clinical oncologists favour radical radiotherapy for localized prostate cancer: a questionnaire survey.

OBJECTIVE: To explore the treatment preferences of clinical oncologists for managing early prostate cancer and to compare the results with the preferences of urologists. METHODS: A postal questionnaire survey was conducted of consultant clinical oncologists in the UK. RESULTS: Consultant clinical oncologists favour radical radiotherapy in most men aged < 70 years, whereas a previous study showed that consultant urologists had a greater preference for radical surgery. CONCLUSION: There is little consensus about which treatment should be used for managing early prostate cancer. There is an urgent need for results from randomized clinical trials to determine the optimum treatment.

Aged↗
PubMed1999

Accuracy of patient positioning during radiotherapy for bladder and brain tumours.

We report the results of a prospective study to quantify inaccuracies in patient set-up during routine radiotherapy for tumours of the brain and bladder, which took place as part of our departmental development. Knowledge of these inaccuracies is required to put into practice the ICRU 50 recommendations regarding clinical target volume and planning target volume. We measured inaccuracies in two dimensions by comparing portal beam films with the simulator check film. Our method used manual measurements, proved to be a very laborious technique, and demonstrated the need for portal imaging. Ninety-five brain and 97 bladder portal films from 30 brain and 30 bladder patients were examined. Displacements greater than 0.5 cm were seen in 13% of brain treatments in the supero-inferior direction and 1% in the anteroposterior direction. With bladder treatments, displacements greater than 0.75 cm were seen in 12% in the supero-inferior direction and 5% in the lateral direction. These results are consistent with other previous studies. We identified a very small systematic error in the department, which was not [corrected] considered to be clinically significant. These results are discussed with reference to other similar studies and the ICRU 50 recommendations.

Adolescent↗
PubMed1995

High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.

We have conducted a retrospective study of high-dose folinic acid and 5-fluorouracil in 96 patients with advanced colorectal cancer. Patients received 200 mg m-2 (maximum 300-350 mg) folinic acid by infusion over 2 h followed by an i.v. bolus of 5-fluorouracil 400 mg m-2 then an infusion of 5-fluorouracil 600 mg m-2 over 22 h. This was repeated over the next 24 h. The schedule was given every 2 weeks for four cycles; thereafter patients with objective response continued to a maximum of eight cycles. The overall response rate was 10.6% in 85 evaluable patients. The median duration of response was 11 months. The median survival was 6 months. Toxicity was low, only one patient experiencing toxicity greater than WHO grade II (grade IV platelet toxicity). Diarrhoea, nausea, vomiting and mucositis also occurred but were mild and infrequent. Our low response rate may be related to factors such as patient characteristics or duration of treatment.

Adult↗